May 29 (Reuters) - China's Innovent Biologics and U.S. pharma giant Pfizer have agreed to a global licensing and ...

When his family came to see him at Beijing Cancer Hospital, they were out of options — and out of hope. Then a renowned ...

Clinical trials in China are getting attention at an international oncology gathering in Chicago. China’s surging biotechnology industry is fueling alarm that U.S. dominance in the field is waning.

Researchers identify trends in healthcare access and use that should inform future pandemic policies SEATTLE – May 20, 2026 – A PLOS Medicine analysis led by Fred Hutch Cancer Center researchers ...

By Siddhi Mahatole May 21 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment ...

Researchers have developed a handheld cancer-screening device capable of detecting early-stage cancer biomarkers from ...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the China subpopulation of the global Phase 3 innovaTV 301 study, ...

Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was ...

Esophageal cancer, a highly aggressive malignancy originating in the esophageal epithelium, poses significant public health challenges in China, where it ranks sixth in incidence and fifth in ...

The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ...